Acquired three products with a combined brand/generic annual market size of $20 million. Filed four new internally created ANDAs with a combined annual marketplace size of $190 million. Received FDA approval for injectable Levofloxacin 25mg/mL single-use vials. Consolidated income for the second one fourth of 2011 was $32.1 million, up 59 percent over the comparable prior year quarter consolidated revenue of $20.2 million. The increase in revenue was the consequence of partial one fourth AVR sales totaling $3.7 million, the continued growth of items launched this year 2010, strong organic growth in established injectable and ophthalmic products and an increase in seasonal allergy ophthalmic sales.Dr Julian Gilbert, Acacia Pharma's CEO commented, ‘We are delighted with these outcomes. Dry mouth is a distressing and common issue in advanced cancer individuals that’s significantly under-recognised. It is associated with a wide range of oral and systemic problems and can contribute to a greatly reduced quality of life. Our market research indicates a locally delivered, liquid formulation of a suitable salivary stimulant will be of major advantage to many cancer sufferers, and these data show that APD515 should satisfy this profile.’ The randomised, double-blind, placebo-controlled, cross-over trial was carried out in 11 centres in the UK and Denmark, and enrolled 32 individuals with advanced malignancy and a persistently dried out mouth.